This article provides a nice summary of progress in using biomarkers to help treat cancer. One of the key takeaways is how much potential there is to understand the precise differences in tumors, and how different drugs will affect each of them. The article references "matrix style" trials as a way to get at this level of patient response detail (e.g. 200 sequenced patients x 14 drugs). Good efficacy biomarkers will make such trials able to deliver positive hits even more rapidly.